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RESEARCH ARTICLE Open Access
The impact of disease-related symptoms
and palliative care concerns on health-
related quality of life in multiple myeloma:
a multi-centre study
Christina Ramsenthaler1*, Thomas R. Osborne1, Wei Gao1, Richard J. Siegert1,2, Polly M. Edmonds3,
Stephen A. Schey4 and Irene J. Higginson1
Abstract
Background: Multiple myeloma, the second most common haematological cancer, remains incurable. Its incidence
is rising due to population ageing. Despite the impact of the disease and its treatment, not much is known on who
is most in need of supportive and palliative care.
This study aimed to (a) assess symptom severity, palliative care concerns and health-related quality of life (HRQOL)
in patients with multiple myeloma, and (b) to determine which factors are associated with a lower quality of life.
We further wanted to know (c) whether general symptom level has a stronger influence on HRQOL than disease
characteristics.
Methods: This multi-centre cross-sectional study sampled two cohorts of patients with multiple myeloma from
18 haematological cancer centres in the UK. The Myeloma Patient Outcome Scale (MyPOS) was used to measure
symptoms and concerns. Measures of quality of life included the EORTC QLQ-C30, its myeloma module and the
EuroQoL EQ-5D. Data were collected on socio-demographic, disease and treatment characteristics and phase of
illness. Point prevalence of symptoms and concerns was determined. Multiple regression models quantified
relationships between independent factors and the MyPOS, EORTC global quality of life item and EQ5D Index.
Results: Five-hundred-fifty-seven patients, on average 3.5 years (SD: 3.4) post-diagnosis, were recruited. 18.2 %
had newly diagnosed disease, 47.9 % were in a treatment-free interval and 32.7 % had relapsed/progressive
disease phase. Patients reported a mean of 7.2 symptoms (SD: 3.3) out of 15 potential symptoms. The most
common symptoms were pain (72 %), fatigue (88 %) and breathlessness (61 %). Those with relapsed/progressive
disease reported the highest mean number of symptoms and the highest overall palliative care concerns
(F = 9.56, p < 0.001). Factors associated with high palliative care concerns were a general high symptom level,
presence of pain, anxiety, low physical function, younger age, and being in the advanced stages of disease.
Conclusion: Patients with multiple myeloma have a high symptom burden and low HRQOL, in the advanced and
the earlier stages of disease. Identification of patients in need of supportive care should focus on assessing
patient-reported outcomes such as symptoms and functioning regularly in clinical practice, complementary to
traditional biomedical markers.
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Background
Haematological malignancies belong to the most com-
mon cancers worldwide [1]. Multiple myeloma is the
second most common haematological malignancy with
an incidence of 3.29 to 4.82 per 100,000 individuals per
year worldwide [2]. Multiple myeloma is characterised
by a specific pattern of end-organ damage with destruc-
tion of the bones, bone marrow failure and renal failure.
With the introduction of novel therapies and autologous
stem-cell transplantation survival has been extended, es-
pecially for patients younger than 60 years [3]. However,
since multiple myeloma remains an incurable disease,
life expectancy is limited. 40.3 and 20.5 % of patients
survive 5 and 10 years, respectively [3, 4]. Despite
improvements in therapies, patients face progressive
disease, interspersed with intervals of stable disease with
minimal or maintenance treatment [5]. Symptoms may
persist into treatment-free intervals [6], added onto
which treatment-related toxicity further impacts on
health-related quality of life (HRQOL) [7, 8].
There is evidence that myeloma patients suffer more
symptoms and problems than other haematological can-
cers. A study from Denmark reported a mean symptom
level of 5.6 symptoms with 2.3 symptoms identified as
severe [9]. Myeloma patients reported the highest level
of pain, fatigue and constipation, alongside problems
with physical, role, and social function [9, 10]. A study
from the Eindhoven cancer registry including myeloma
patients up to 10 years post-diagnosis and comparing
results with an age- and gender-matched normative
population, found similarly diminished and clinically
relevant compromises in all functioning subscale scores
of the EORTC QLQ-C30 questionnaire [11]. Again,
symptoms of pain, fatigue, but also breathlessness,
nausea and vomiting and peripheral neuropathy were re-
ported by patients to be the most bothersome symptoms
[11]. The general high symptom level and the import-
ance of high symptom burden in conjecture with mental
health symptoms were identified as strong determinants
of health-related quality of life (HRQOL) in a recent
study enrolling myeloma outpatients in a multi-centre,
cross-sectional study [12].
Longitudinal observational evidence of how HRQOL
changes over the disease course focuses entirely on stem
cell transplantation populations. Here, results mainly
support the fact that myeloma patients experience a high
symptom burden even before stem cell collection, as
shown in a study with 94 patients receiving high dose
melphalan and autologous stem cell transplantation,
reporting at least moderate fatigue, pain, anxiety and
depression at baseline [13]. After transplantation most
symptoms improved, but depression and overall quality
of life deteriorated. That recovery to full functioning and
symptom levels prior to therapy is often not possible for
patients with myeloma was demonstrated by a cross-
sectional postal survey of 650 patients at different
disease stages [6]. Recovery during subsequent
treatment-free intervals was often not fully achieved
and patients lived with a profound impact of the disease,
its disease-related symptoms but also treatment-related
toxicities [6].
Thus, the disease is an example of the changing face
of cancer with patients experiencing a chronic disease
trajectory [14] during which a variety of symptoms,
psychological and social factors impact on patients’ qual-
ity of life. However, the aspect of quality of life is still
underrepresented in myeloma research, both as an out-
come in evaluation of cancer treatment and in impacting
treatment and supportive care guidelines [15, 16].
Descriptive studies of HRQOL are mainly cross-
sectional in nature and focus on treatment or trial popu-
lations that receive autologous stem cell transplantation
[17–22]. However, information on patients in later treat-
ment phases is mainly lacking. Only one study by Boland
and co-authors enrolled patients at a median of 5.5 years
post diagnosis, including patients in later treatment
intervals [23]. Thus, relatively little is known about how
HRQOL and physical and psychosocial symptoms
change over time and in the advanced stages of disease.
This information would be vital to understand when pa-
tients experience periods in the disease trajectory during
which they would benefit from additional support. This
would help target services to those individuals most at
risk, who could then benefit from early and preventive
supportive care interventions. Further, the role of gen-
eral symptom level and other disease- and treatment-
related determinants in their influence on HRQOL re-
mains conflicting [12, 16]. In focusing on the advanced
stages of myeloma, existing and commonly used ques-
tionnaires such as the EORTC QLQ-C30 might underre-
present some of the problems and concerns regarding
information and service provision that are of particular
interest to myeloma patients [24]. We therefore wanted
to focus on further problems and concerns that are im-
portant to patients with multiple myeloma, in addition
to symptom burden, and to understand how symptom
burden and problems differ during different treatment
phases.
In this study we sought to determine the prevalence and
severity of common symptoms and problems in patients
with multiple myeloma at various stages of their disease,
specifically for those with relapsed or progressive disease;
and to determine whether patients in the advanced stages
of myeloma experience a different symptom and problem
profile than patients in earlier stages. We also sought to
determine which demographic and disease characteristics
were associated with a lower quality of life and more
symptoms and problems, testing the hypothesis whether
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general symptom level and specific symptoms had a stron-
ger influence on HRQOL than disease characteristics.
Methods
Study design and participants
For this multisite, cross-sectional study patients with mul-
tiple myeloma were recruited from both inpatient stem cell
transplantation units and outpatient haematology clinics in
18 centres in the United Kingdom. Participating hospitals
included a mixture of tertiary transplant centres and district
general hospitals to ensure a representative sample of pa-
tients from different settings. The analysis for this study
consists of two cohorts of patients that were recruited 1
year apart (cohort 1 was recruited from February 2013 to
August 2013 and cohort 2 was recruited from April 2014
to September 2014) – one cohort for validating a new ques-
tionnaire to measure disease-specific quality of life in mul-
tiple myeloma (the Myeloma Patient Outcome Scale,
MyPOS) (n = 380 myeloma patients) and one cohort for a
longitudinal study, determining the impact of physical and
mental symptoms on quality of life, and enrolling patients
with multiple myeloma that were either newly diagnosed or
had received treatment before (n = 235 myeloma patients).
Inclusion criteria for both studies were: age ≥18 years,
confirmed diagnosis of multiple myeloma that had been
disclosed to the patient, and the capacity to give in-
formed written consent. Exclusion criteria were: Patients
who were too unwell, distressed or symptomatic to par-
ticipate as judged by their clinical team, patients with se-
vere neutropenia or for whom myeloma was not the
most important health problem.
Procedures
Consecutive patients were screened by a member of the
clinical team for eligibility before being approached by cli-
nicians in the clinic or on the ward. If they signalled inter-
est they then met with a research nurse who explained the
study and obtained written consent. All were informed
that participation was voluntary and would not affect the
medical management in any way. At this point the re-
search nurse also completed the demographic information
with the participant. The patient-reported questionnaires
were completed by patients in paper format either during
their clinic visit or at home. In case of completion at
home, patients were supplied a pre-paid envelope for
returning the questionnaires to the institute. Information
on patients’ medical history and the treatments they had
received was extracted from the medical notes by the cli-
nicians or research nurses with the permission of the
patient. All non-participants (those who were ineli-
gible and those who declined) were asked for consent
to record limited demographic and treatment details
in order to compare these against the study sample.
Data collection and measures
Patient-reported outcome variables
The two main outcomes of the study, quality of life and
symptom burden/palliative care concerns, were assessed
using two generic and two disease-specific question-
naires. Choice of patient-reported outcomes was based
on a systematic review of HRQOL validated in multiple
myeloma [25]. Generic quality of life was measured with
the European Organization for Research and Treatment
of Cancer (EORTC) quality of life questionnaire QLQ-
C30 (version 3) [26] and the EuroQOL 5D-3L question-
naire [27]. One myeloma-specific quality of life question-
naire, the EORTC QLQ-MY20 [28, 29], was used to
reflect disease-specific symptoms and concerns. Both
the generic and the disease-specific version of the
EORTC were chosen as they have undergone the most
extensive psychometric validation in myeloma patients
[25], are considered to be the gold standard in clinical
trials [15] and therefore give a valid account of HRQOL
in multiple myeloma. Scores from the EORTC QLQ-
C30 were linearly transformed and subscales were
formed according to the published guidelines [30].
For the myeloma module QLQ-MY20, the two symp-
tom subscales and two functional subscales were
formed according to the guidelines published in the
initial validation study [28, 29]. For the EuroQOL
5D-3L questionnaire, the US norms were used to
convert the health states into the single summary
index [27].
The Myeloma Patient Outcome Scale (MyPOS) [31]
formed the main outcome for determining point preva-
lence of disease- and treatment-related symptoms and to
measure palliative care concerns, such asconcerns re-
garding functional ability in daily life, feeling at peace,
concerns regarding the future and fear of dying, infor-
mation needs and concerns regarding practical matters
and financial burden of disease (for all items in the ques-
tionnaire see Additional file 1: Figure S1). Palliative care
concerns in this context focus on the outcomes that re-
flect the specific goals of palliative care, namely to pro-
mote an individual’s quality of life and to relieve any
distressing symptoms and to offer emotional, spiritual
and psychological support [32]. The MyPOS therefore
focuses on assessing those areas that are key domains
for patients experiencing a higher disease burden. The
MyPOS is the only available questionnaire that assesses
outcomes important to palliative care in late stage and
earlier but symptomatic disease across settings [32].
The generic and disease-specific outcome measures in
their combination allow to determine which myeloma
patients experience a high burden, either through a
high symptom level, high burden from specific symp-
toms or from wider psychological, spiritual or practical
concerns.
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The presence of clinically relevant anxiety or depres-
sion was measured using the Hospital Anxiety and
Depression Scale (HADS) [33], both of which are com-
mon problems in cancer patients and might be import-
ant problems associated with burden and HRQOL. The
Hospital Anxiety and Depression Scale is a validated
self-report questionnaire consisting of 14 items, seven
items each assessing depression or anxiety with the two
subscale scores ranging from 0 to 21. A cut-off point of
8 out of 21 per subscale is used to define clinical cases
of depression or anxiety, respectively, and higher scores
indicate higher depression or anxiety [34].
Table 1 presents a short description of each outcome
measure and its scoring procedure.
Sociodemographic and clinical information assessed via
patient interview
Demographic information on age, gender, marital status,
ethnicity, religion, educational level and occupation sta-
tus was obtained directly from the patient. Performance
status was assessed by applying the Eastern Cooperative
Oncology Group (ECOG) scale with 0 ‘Fully active’ to 4
‘Completely disabled’ [35].
Table 1 Data collection and questionnaires for outcome collection
Measure Description
Symptom status and
palliative care concerns
Myeloma Patient Outcome Scale (MyPOS) [31] 33-item questionnaire with 15 disease- and treatment-specific symptoms,
13 myeloma-specific quality of life items, 5 generic items about palliative
care concerns
Module of the Palliative Care Outcome Scale [32]
Three subscales: Functioning and symptoms, Emotional response, Healthcare
support (information and satisfaction with care) [31]
5-point Likert scale (0 – not at all to 4 – overwhelming)
Possible range of 0–132 for total score (higher score means more
symptoms/problems)
Health-related
quality of life
European Organization for Research and
Treatment of Cancer (EORTC) QLQ-C30 [26]
30-item generic health-related quality of life questionnaire
Five functional scales (physical, role, emotional, social, cognitive functioning),
six symptom scales (fatigue, nausea/vomiting, pain, dyspnoea, constipation,
appetite loss, sleeping problems, financial difficulties), one global health
status/quality of life scale
4-point Likert scale (1 – not at all to 4 – very much), except for two 7-point
global health status/quality of life items
Transformation of all scales to 0–100 scale [30]
High scores on functional scales and global quality of life scales represent
high level of functioning/quality of life
High scores on symptom scales represent a high symptom burden
EORTC-QLQ-MY20 [28, 29] 20-item add-on module of disease-specific symptoms and functional impact
for multiple myeloma, added onto the EORTC-QLQ-C30
Two symptom subscales (disease symptoms and side-effects of treatment),
two functional subscales (body image and future perspectives)
4-point Likert scale (1 – not at all to 4 – very much)
Transformation of all scales to 0–100 scale
High scores on functional scales represent high levels of functioning. High
scores on symptom scales represent a high symptom burden.
EuroQOL-5D-3L [27] Time trade-off utility measure from a 5-item health status assessment and
a visual analogue scale (generic health state outcome)
5 items: mobility, self-care, usual activities, pain/discomfort, anxiety/depression;
global health status measured by one visual-analogue scale (0–100)
3-point Likert scale for 5 items (no problems, some/moderate problems,
extreme problems)
Five items form EQ5D Index score, transformed into health status
Range of −0.59 to 1.0 points (higher scores indicate better health state with
1.0 representing full health), standardised according to country-specific norms
(UK and US norms)
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Disease and treatment details extracted from medical records
Disease and clinical details were extracted from the pa-
tient’s medical notes. These were information on the
date of diagnosis, the immunoglobulin type (Ig), and the
clinical stage of myeloma. The International Staging Sys-
tem (ISS) [36] for myeloma was used to stage the disease
at diagnosis on the basis of the reported β2-microglobu-
lin and albumin parameters in the clinical notes. Time
since diagnosis in months as a measure of disease dur-
ation was calculated by subtracting the date of the
interview from the data of diagnosis. The current phase
of illness was classified as newly diagnosed (pre-treat-
ment or undergoing first-line treatment), being in a
treatment-free interval (watch and wait or stable
disease with no evidence of disease progression) or
relapsed/progressive disease (second line therapy or
above, lack of response or progression on treatment or
receiving palliative care) [37].
Treatment details were also extracted from the med-
ical records. It was recorded whether patients were cur-
rently on treatment, the types and dates of current and
previous treatments and the response to these treat-
ments [38]. From this information, a classification was
derived of current and previous treatments, treatment
intensity, number of lines of treatment received and
whether patients were in a treatment or a treatment-free
interval at the time of the survey. A treatment line was
defined as any active or maintenance treatment a patient
received for their myeloma disease, either as first-line
treatment or after a relapse. Treatment-free intervals
were intervals during which patients were classified as
being in remission, receiving no active or maintenance
treatment or receiving supportive treatments only (e.g.
anaemia medication or bisphosphonates).
Statistical analysis
Apart from one item (worry about sex life) on the
MyPOS, missing data were less than 5 % of participants
on most dependent and independent variables and
tested to be missing at random. For descriptive analyses
we did not impute missing values [39]. Handling of
missing data in the multivariate analyses involved run-
ning a complete-case analysis as the first step und using
multiple imputation in a second step [40].
Data analysis for objective (a), the description of symp-
tom severity, palliative care concerns and HRQOL,
involved determining the point prevalence with 95 %
confidence intervals of MyPOS symptoms (if reported at
least as ‘slight’). The X2-test was used for comparison of
symptom burden across disease phases. The total
MyPOS score (total palliative care concerns) and sub-
scale scores of the MyPOS were compared between dis-
ease phases using univariate analysis of variance.
For objective (b), determining the factors associated
with a lower quality of life and higher palliative care
concerns, we used multiple linear regression models.
The total MyPOS score, global quality of life scale of the
QLQ-C30 and the EQ5D Index were the dependent vari-
ables and symptom and patient characteristics were
independent variables. We built regression models for
each outcome variable separately. Data cleaning and
testing of assumptions for regression techniques
(normality, skewness, kurtosis, outliers, linearity) were
performed before analysis [39]. Total scores on the
MyPOS, the EORTC and EQ 5D questionnaires satisfied
assumptions for multivariate analysis. Multicollinearity
assessment showed multicollinearity of the physical
functioning subscale in the EORTC-QLQ-C30 and the
“mobility” item in the MyPOS. The latter, due to its bet-
ter statistical distribution, was kept in the analysis. The
following strategy was used to prioritise variables for in-
clusion in the models: univariate linear regression
models tested each of the 15 symptoms against the three
outcomes. Those that were statistically significant (Bon-
ferroni-corrected alpha level <0.003) were combined in a
multivariate model that was then trimmed to exclude
variables that lost significance. The initial set of clinical,
treatment and demographic variables was based on a
systematic review of predictors for HRQOL in multiple
myeloma [41].
To test objective (c), determining whether general
symptom level had a stronger influence on HRQOL
than disease characteristics, we used hierarchical
regression procedures. We adjusted models for each
outcome variable for the influence of general symptom
level (total number of symptoms on the MyPOS).
Socio-demographic, disease and treatment history
variables as well as HADS depression and anxiety
scores found to be significant in bivariate analyses were
entered into the multivariate model, which was further
reduced by excluding non-significant factors.
Sample size calculations in G*Power software [42]
for multiple linear regression analyses using 15 predic-
tors, power = 80 %, α = 0.05 and a medium effect size
of F = 0.15 for regression [43] suggested a sample size
of 139, which was well exceeded in this analysis.
All analyses were conducted using SPSS 22 [44].
Ethical issues
Research Ethics Committee approval was granted by the
South East London REC-3 (ref 10/H0808/133) and by
the Central London REC (13/LO/1140). Local permis-
sions from the Research & Development departments of
all 18 participating NHS hospital trusts were obtained.
A complete list of participating trusts can be found in
the Declarations section.
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Results
Overall, 1041 patients with multiple myeloma were
screened in both studies, of which 869 fulfilled the
inclusion criteria and were approached. Completed
questionnaires were received from 557 participants.
One-hundred-seventy-two patients were ineligible for
recruitment, 218 declined to participate and 33 were
consented but the completed questionnaire was not re-
ceived. Reasons for ineligibility and non-participation
are detailed in Fig. 1.
Table 2 displays the sample characteristics of 557
myeloma patients. Their mean age was 68.4 years (SD
10.4; median: 69 years, range: 34–92 years) with a
higher proportion of men taking part (61.4 %). Most
participants were in a treatment-free interval; a mean
42.5 months post diagnosis; 139 (25.5 %) patients had
been living with myeloma 5 years or longer. Two-
hundred-fifty-eight (46.5 %) participants were currently
not on active or maintenance treatment. The median
number of lines of treatment received was one.
Fig. 1 Cross-sectional analysis of symptom burden and palliative care needs in multiple myeloma: Flow chart of two study cohorts merged in analysis
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Prevalence of myeloma-specific symptoms and concerns
Patients reported a mean of 7.2 symptoms (SD = 3.3,
median: 7, range: 0–15). The most burdensome symp-
toms, scored as ‘severe’ or ‘overwhelming’ on the
MyPOS, were fatigue (with 21.9 % scoring it as burden-
some), pain (13.8 %), and tingling in the hand/feet
Table 2 Demographic and clinical characteristics of 557 patients
with myeloma included in the study
Patients
Variable n %
a) Socio-demographic details
Age: Mean (SD, range) 68.41 (SD 10.4; 34–92)
Gender
Men 341 61.2
Women 209 37.5
Missing 7 1.3
Ethnicity
White British/Irish/Other white
background
513 92.1
Black African or Black Caribbean 19 3.4
Mixed ethnic background 4 0.7
Other 14 2.5
Missing 7 1.3
Marital status
Single 44 7.9
Married 400 71.8
Divorced or separated 36 6.5
Widowed 68 12.2
Missing 9 1.6
Occupational status
Working or student 82 14.7
Not working or retired 467 83.9
Missing 8 1.4
b) Disease factors
Current phase of illness
Newly diagnosed 102 18.3
Treatment-free interval/stable disease 266 47.8
Relapsed/progressive/palliative stage 182 32.7
ISS stage at diagnosis
I 154 27.6
II 109 19.6
III 116 20.8
Missing 178 32.0
Time since diagnosis in years: Mean (SD) 3.53 (3.4)
Median, range (in years) 2.5 (0.08–23.6)
Immunoglobulin type
IgG 314 56.4
IgA 118 21.2
Kappa or lambda light chain 95 17.1
Other 15 2.7
Missing 15 2.7
Table 2 Demographic and clinical characteristics of 557 patients
with myeloma included in the study (Continued)
ECOG performance status
0 Fully active 188 33.8
1 Restricted 222 39.9
2 Unable to work 87 15.6
3 or 4 – Limited selfcare/confined 50 9.0
Missing 10 1.8
Total number of symptoms on MyPOS
0 5 0.9
1–5 175 31.4
6–8 168 30.2
9–15 205 36.8
Missing 4 0.7
d) Treatment factors
Lines of treatment: Median (range) 1 (0–6)
Previously untreated 30 5.4
1 line received 249 44.7
2 lines received 155 27.8
3 or more lines received 123 22.1
Currently on treatment 292 52
Active chemotherapy 213 –
Undergoing autologous stem cell
transplant
5 –
Maintenance therapy 74 –
Current MM treatment
Bortezomib 59 27.6
Lenalidomide 89 41.9
Thalidomide/Pomalidomide 56 26.5
Alkalyting agent 111 51.9
Other 2 0.9
Combination chemotherapy 110 51.4
Intensity of treatments received
None 54 9.7
Chemotherapy only 303 54.4
Chemotherapy and stem cell transplant 161 28.9
More than one transplant 32 5.7
Missing 7 1.3
Abbreviations: ECOG Eastern Cooperative Oncology Group performance status,
ISS International staging system classification of myeloma [36], MyPOS: Myeloma
Patient Outcome Scale, SD Standard deviation
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(10.2 %) (Fig. 2 and Additional file 1: Table S1). Three
symptoms were present in 60–88 % of patients - pain
(71.5, 95 % CI: 67–76 %), fatigue (87.6, 95 % CI: 85–
90 %) and breathlessness (60.8, 95 % CI: 57–65 %). Diffi-
culty remembering things, tingling in the hand/feet and
poor mobility were present in 50–70 % of participants.
Less prevalent symptoms were constipation (38.3 %),
mouth problems (sore or dry mouth, 37.3 %), anxiety
(31.5 %), nausea (29.3 %), diarrhoea (23.2 %), depression
(22.8 %) and vomiting (10.1 %).
The most burdensome problems and concerns existed
in the domains functioning, emotional wellbeing, and
information needs. These included problems with car-
rying out usual activities (32.3 %); worrying that the
illness might get worse (40.4 %), and not having
enough information about what might happen in the
future (29.4 %). The mean total MyPOS score was 21.5
(SD = 13.4), indicating a moderate level of concerns.
Symptoms and concerns per treatment phase
The prevalence and severity of symptoms differed
according to disease phase. Of the three groups – newly
diagnosed, treatment-free interval, and relapsed/progres-
sive disease - those with relapsed/progressive disease
had the highest mean number of symptoms (M = 5.91,
SD = 2.63; versus M = 4.91 in the newly diagnosed group
and M = 4.77 in a treatment-free interval). On the symp-
tom level, differences between disease phases were found
for shortness of breath (X2: 12.5, p = 0.002), constipation
(X2: 8.1, p = 0.018), mouth problems (X2: 9.98, p = 0.007),
and tingling in the hands and feet (X2: 18.93, p < 0.001)
with more patients in the relapsed/progressive phases
of disease suffering from these symptoms than ex-
pected (Table 3).
Similarly, patients with relapsed/progressive disease had
the highest mean total MyPOS score (M = 24.68), followed
by newly diagnosed patients (M = 23.1) and patients in a
treatment-free interval (M = 18.8). On the subscale
level, univariate analysis of variance showed that
differences exist in Functioning/Symptoms (F = 11.919,
p = 0.001) and the Emotional response subscale (F = 5.36,
p = 0.005) between the phases with post-hoc tests indi-
cating that patients with relapsed and progressive dis-
ease have more problems in these areas than those in
the stable phases of myeloma (Fig. 3).
A more fine-grained analysis of phase according to
treatment (number of treatment lines or treatment-free
interval), shown in Fig. 4, was conducted to better
Fig. 2 Prevalence and severity of individual symptoms and other problems as reported on the MyPOS (%) for n = 557 patients. Symptoms and
problems in each category are listed in order of severity
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Table 3 Outcome data scores for total sample and comparison of symptoms and palliative care needs across disease phases
Score Newly diagnosed (n = 102) Stable (n = 268) Progressive, relapsed stage
(n = 184)
Test
Measure n Mean, SD Median (range) n Mean, SD Median (range) n Mean, SD Median (range) n Mean, SD Median (range) F value p
Time since diagnosis (months) 552 42.3 (40.7) 29.9 (0.1–283) 102 10.4 (16.8) 4.6 (0.2–103.1) 267 44.2 (39.8) 30.4 (0.49–239.9) 183 57.3 (41.8) 57.3 (41.8) 52.2 0.001*
ECOG Performance status 551 – 1 (0–4) 101 – 1 (0–3) 268 – 1 (0–4) 182 – 1 (0–4) X2: 24.4 0.002
MyPOSa
Total score 468 21.5 (13.5) 19 (0–61) 86 22.9 (13.4) 20 (1–61) 229 18.9 (13.1) 17 (1–59) 150 24.7 (13.4) 23 (0–61) 9.6 0.001
Symptoms and function 526 76.2 (16.6) 78.8 (30.4–100) 96 75.8 (14.5) 76.8 (36–100) 253 79.1 (14.3) 80.4 (30.4–100) 175 72.2 (14.8) 71.4 (34–100) 11.9 0.001
Emotion and coping 499 80 (16.6) 84.4 (18.8–100) 94 77.1 (17.2) 81.3 (34–100) 244 82.4 (16.2) 87.5 (18.8–100) 158 77.9 (16.4) 81.3 (34–100) 5.3 0.005
Healthcare support and
information needs
544 90.8 (12.7) 95 (40–100) 99 91.2 (12.8) 95 (40–100) 264 91.1 (12.9) 100 (40–100) 178 89.8 (12.5) 95 (50–100) 0.6 0.532
EORTC-QLQ-C30b
Global health status 555 61.2 (22.3) 66.7 (0–100) 102 59.5 (20.5) 66.7 (0–100) 267 65.8 (21.8) 66.7 (0–100) 183 55.2 (22.7) 50 (0–100) 12.9 0.001
Physical function 554 61.5 (22.5) 60 (0–100) 101 61.2 (26.7) 66.7 (0–100) 266 65.3 (25.2) 66.7 (0–100) 184 56.2 (24.6) 53.3 (0–100) 6.9 0.001
Role function 553 59 (33.1) 66.7 (0–100) 101 55.4 (35.6) 66.7 (0–100) 266 64.9 (30.9) 66.7 (0–100) 183 52.3 (33.5) 50 (0–100) 8.9 0.001
Emotional function 555 76.2 (22.1) 83.3 (0–100) 102 74.5 (23.7) 83.3 (0–100) 267 77.3 (21.3) 83.3 (0–100) 183 75.3 (22.3) 75 (0–100) 0.8 0.459
Cognitive function 555 79 (21.9) 83.3 (0–100) 102 78.1 (21.9) 83.3 (0–100) 267 81.2 (20.5) 83.3 (16.7–100) 183 76.3 (23.7) 83.3 (0–100) 2.8 0.060
Social function 554 65.1 (31.5) 66.7 (0–100) 102 60.5 (34.8) 66.7 (0–100) 267 70.2 (29.3) 66.7 (0–100) 182 60.1 (31.7) 66.7 (0–100) 7.1 0.001
EORTC QLQ-MY20c
Disease symptoms 549 73.9 (21.2) 77.8 (0–100) 101 75.7 (20.9) 77.8 (0–100) 262 74 (20.9) 77.8 (5.6–100) 183 72.7 (21.8) 77.8 (0–100) 0.6 0.530
Side-effects of treatment 542 81.4 (14.4) 83.3 (0–100) 100 80.3 (14) 83.3 (43–100) 261 83.5 (14) 86.7 (30–100) 178 78.8 (14.9) 80 (23–100) 6.1 0.002
Body image 551 77.9 (30.5) 100 (0–100) 100 79 (31.7) 100 (0–100) 265 79.6 (28.2) 100 (0–100) 183 74.9 (32.8) 100 (0–100) 1.4 0.247
Future perspective 549 64.6 (26.5) 66.7 (0–100) 100 61.4 (28.1) 66.7 (0–100) 264 67.2 (25.1) 77.8 (0–100) 182 62.1 (27.3) 66.7 (0–100) 2.8 0.061
EuroQOL-5D-3L
EQ5D Index score 550 0.65 (0.28) 0.69 (−0.5–1) 101 0.66 (0.28) 0.69 (−0.18–1) 264 0.67 (0.27) 0.69 (−0.18–1) 182 0.59 (0.29) 0.69 (−0.35–1) 4.5 0.012
EQ5D Visual analogue scale VAS 318 63.51 (20.02) 61 (0.5–100) 68 58.8 (19.8) 60 (0.5–96) 139 69 (19.6) 69.5 (11–100) 111 59.5 (19.1) 60 (10–100) 9.82 0.001
aMyPOS: Myeloma Patient Outcome Scale: comprises 27 items, higher scores indicate higher symptom burden/more palliative care needs, MyPOS subscale scores transformed to 0–100 scale to allow for comparison to
subscale scores from the EORTC QLQ-C30 and –MY20 questionnaires
bEORTC QLQ-C30: For the EORTC-QLQ-C30, higher scores on functioning subscales and the global quality of life scale indicate better functioning/better quality of life
cEORTC-QLQ-MY20: For the myeloma module of the EORTC quality of life questionnaire higher scores indicate more problems/symptoms in subscales
*Bold values denote significant p-values (>0.05)
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Fig. 3 Differences in the total MyPOS and MyPOS subscales in three phases of myeloma disease
Fig. 4 Mean MyPOS symptoms and subscale scores per treatment phase. A higher score indicates a higher symptom burden in the individual
symptom items. Line line of treatment, MyPOS Myeloma Patient Outcome scale, SOB Shortness of breath, TIF treatment-free interval
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understand the differences in symptom burden and
problems according to phase. The symptoms fatigue,
pain and shortness of breath showed a high severity
throughout all treatment phases, with the latter being
overtaken by tingling in the hands and feet as the third
most severe symptom from the second treatment-free
interval onwards. Scores for all symptoms tended to be
higher during treatment-intervals than in treatment-free
intervals. Scores for sore or dry mouth, diarrhoea,
tingling in the hands/feet, shortness of breath and diffi-
culties remembering were highest for those participants
in the later phases of disease.
Factors associated with myeloma-specific problems and
concerns
All symptoms and functioning scales of the EORTC
QLQ-C30 were significantly associated in bivariate ana-
lyses with the total MyPOS score. The only demographic
characteristic being associated with high palliative care
concerns was age (see Additional file 1: Tables S2 and
S3). Clinical characteristics that were significantly differ-
ent for those in the lower vs higher half of the MyPOS
total score distribution were phase of illness (with a
higher proportion of newly diagnosed and relapsed pa-
tients reporting a higher MyPOS total score), receiving
treatment, an ECOG performance status of 2 and gen-
eral symptom level. In the first multivariate model and
after adjusting for general symptom level, only the
symptoms fatigue, pain, anxiety, dry mouth and the
physical function and social function subscales remained
significantly independently associated with the outcome.
The final parsimonious multivariable model with demo-
graphic and clinical factors showed significant associations
of general symptom level, pain, anxiety, dry mouth, phys-
ical function, age, and being either in the newly diagnosed
or relapsed/progressive disease phase with high palliative
care concerns (see Table 4).
Multiple regression analysis of quality of life
In the first multivariate model including all symptoms
and demographic and clinical characteristics found posi-
tively associated in the bivariate analyses (see Additional
file 1: Tables S2 and S3), only the symptoms pain,
fatigue, anxiety and depression as well as poor mobility
Table 4 Regression models for outcome variables a) palliative care concerns (total MyPOS score), b) global quality of life
(EORTCQLQ-C30 subscale), and c) generic health-related quality of life (EQ5D Index score) and their association with demographic, clin-
ical characteristics and symptom burden (n = 557)
Palliative care concerns Global quality of life QLQ-C30 EQ5D Index
Independent variables Coefficient Lower CI Upper CI Coefficient Lower CI Upper CI Coefficient Lower CI Upper CI
(Constant) 20.639** 14.189 27.089 105.788** 100.986 110.589 1.168** 1.093 1.242
General symptom level 1.439** 1.136 1.741 – – – – – –
Pain 0.046* 0.016 0.076 −2.572* −4.168 −0.975 −0.100** −0.129 −0.071
Weakness/lack of energy – – – −5.741** −7.395 −4.086 – – –
Drowsiness – – – – – – 0.032 0.000 0.064
Dry mouth 1.395** 0.558 2.233 – – – – – –
HADS Anxiety 1.100** 0.891 1.308 −2.519* −4.091 −0.947 – – –
HADS Depression – – – −3.749** −5.446 −2.052 −0.075** −0.102 −0.048
Age −0.136** −0.204 −0.069 – – – – – –
Being in the stable/plateau phasea −2.693** −4.096 −1.290 4.804** 2.127 7.482 – – –
ECOG performance status 2b – – – −3.654 −7.449 0.141 – – –
ECOG performance status 3/4 –
limited self-care or completely disabledc
– – – – – – −0.159** −0.248 −0.070
Physical function/Poor mobility −0.138** −0.174 −0.101 −5.085** −6.610 −3.560 −0.082** −0.110 −0.054
Adjusted R2 0.879 0.514 0.584
F, P F = 192.205 P < 0.001 F = 85.522 P < 0.001 F = 61.924 P < 0.001
ECOG Eastern Cooperative Oncology Group performance status, CI confidence interval, EQ5D EuroQol-5D-3L, HADS Hospital Anxiety and Depression Scale,
MyPOS Myeloma Patient Outcome Scale
aReference group is patients being unstable, i.e. newly diagnosed or having relapsed, progressive or palliative disease or being in a treatment-interval
bReference group is ECOG performance status of 0
cReference group is ECOG performance status of 0
*p < 0.05
**p < 0.001
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remained significant in their association to the global
quality of life item of the QLQ-C30. Controlling for gen-
eral symptom level did not alter the results. In the final
multivariate trimmed model, the quality of life score was
significantly and independently associated with a higher
pain level, higher fatigue level, more mobility problems,
more anxiety and depression and an ECOG performance
status of 2 (Table 4). Those in a treatment-free interval
experienced better quality of life. The final multivariate
trimmed model for the outcome EQ5D Index score con-
tained the variables pain, drowsiness, poor mobility, de-
pression and ECOG performance status of 2, but no
effect of phase of illness was found, nor an effect of gen-
eral symptom level (Table 4).
Discussion
This is the first study to compare levels of symptom
burden and quality of life problems among patients at
different stages of the disease. We found a persistently
high symptom burden, even during treatment-free
phases of disease in multiple myeloma, and providing
evidence for the association and potential mediation
of general symptom level, pain, fatigue, mental health
and physical function on disease-related problems and
HRQOL.
The findings demonstrate the persistently high symp-
tom burden and compromise in HRQOL, expressed by a
high mean number of symptoms, with pain, fatigue,
symptoms of peripheral neuropathy and breathlessness
as the most commonly reported symptoms. These per-
sist into the later stages of myeloma, thereby confirming
results from the Nordic Myeloma Study group [10] and
from the Eindhoven Profiles registry [11] regarding the
high symptom burden and the importance of pain, fa-
tigue and breathlessness, together with symptoms of per-
ipheral neuropathy, in myeloma. Our analysis expands
these findings by showing that symptoms may well
extend and remain a burden in the treatment-free inter-
vals. A similar persistent high prevalence of pain, neuro-
pathic and other, and fatigue was observed by Boland
and co-authors in a sample of patients with multiply re-
lapsed but stable disease [23]. A lower HRQOL in global
and subdomains of the EORTC QLQ-C-30 and MY-20
measures was also described in a cross-sectional study
by Acaster et al. [6], suggesting persistent symptom bur-
den. However, it should be borne in mind that these
findings come from cross-sectional studies. Longitudinal
observational evidence in myeloma is rare, with the
few studies not using secondary analysis of RCT data
enrolling patients at the stage directly pre or post
first-line treatment and not focusing on advanced
stages [17–22].
One surprising finding was the high prevalence of
breathlessness that was reported by 60.8 % of participants.
The severity of shortness of breath had a mean of close or
above 2.0 in all treatment phases – from diagnosis and
prior to first-line treatment to later phases post the second
treatment-free interval. However, this finding might be ex-
plained by cardiac or pulmonary complications either
resulting from the disease itself, from treatments received
(with patients receiving immunomodulatory agents or
bortezomib being at increased risk of experiencing pul-
monary adverse events) [45, 46], or – given that our study
included a predominantly older population with a mean
age of 68.4 years – also being a consequence of age-
related comorbidities [47]. A limitation of our study is that
number of comorbidities was not assessed and that lack of
assessing this potential confounder might affect the rela-
tionship between symptoms, performance status and
palliative care concerns or quality of life. Future stud-
ies should focus on the relationship between
comorbidity, treatment intensity, disease progression
and HRQOL [48].
To better understand which patients with multiple
myeloma would profit from targeted supportive care in-
terventions, a regression analysis of associations between
patient, disease, treatment characteristics and palliative
care concerns or quality of life was conducted. Multiple
myeloma, despite being an incurable disease with pa-
tients ultimately dying from it, its related complications,
or from the side effects of treatment, is still not recog-
nised as a disease that warrants palliative care involve-
ment [49]. This is mainly due to the disease, like many
other haematological cancers, not following a linear
trajectory of progression in which the end of life is well-
defined. Rather, the progression is interspersed with
intermittent periods of remission and stable disease,
relapse, multiple lines of treatment, the potential for
sudden deterioration and death due to disease- or
treatment-related complications and patients continuing
to receive and to respond to treatment even in advanced
disease [50–52]. Our finding of a persistently high symp-
tom burden, even during treatment-free intervals, shows
that decisions regarding involvement of palliative care to
support and help with the impact on quality of life can-
not be based on clinical response to treatment as this
will miss a substantial number of patients who would
benefit from additional supportive or palliative care
services [53, 54]. This matters because research on needs
in general cancer and myeloma has shown that those
patients with high unmet needs, low quality of life and a
high symptom burden are at increased risk of shortened
survival [55–57].
Results from regression analyses support other au-
thors’ findings of patient’s self-reporting of symptoms
providing independent prognostic information [8, 55,
57]. However, contrary to our hypothesis, we found that
general symptom level did not act as a mediator in the
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hierarchical regression analyses for all outcomes. This
means it is not the high number of symptoms that
might indicate who is in need of supportive care, but
specific symptoms might better serve that purpose.
Especially the presence of pain or fatigue indicates
burden and is associated with high palliative care
concerns; results that are similar to findings by Kripp
et al. [54]. In our study, general symptom level did not
remain independently associated with global quality of life
when sociodemographic and clinical variables were en-
tered into the regression analysis, contrary to a recent
study using a different outcome measure to determine
general symptom level [12]. This might be because Jordan
et al. [12] did not take into account variables like function-
ing. Our findings from the regression analyses support the
hypothesised relationships between symptoms, function,
emotional response and quality of life in the Wilson
and Cleary model [58].
Contrary to the study of predictors for survival in mye-
loma [38], clinical variables such as ISS stage, myeloma
subtype or treatment-related variables did not remain sig-
nificantly independently associated with quality of life in
our study. Other factors, such as low performance status
and pain, do overlap. Depression and anxiety were signifi-
cant factors for all three outcomes. The importance and
persistence of mental health problems have been demon-
strated in other studies, also as predictors for survival [ 55,
57]. Overall, this points towards patients needing more
support in all phases and that focusing resources on the
end of life, which is hard to define in multiple myeloma,
or clinical response criteria misses a potentially large
number of patients who experience a high burden of dis-
ease- and treatment-related problems. Early integration of
palliative care, alongside monitoring of HRQOL and
symptoms, could help targeting supportive care services
towards those in need and might help better symptom
management. These approaches have shown to be
valuable in monitoring treatment adverse events in
haematology [59, 60].
Our study had several limitations. Despite the high
response rate, this was a cross-sectional study with non-
random sampling. Selection bias might limit the validity
of the findings. Although many of the screened and
eligible patients for the study took part and we aimed to
recruit a consecutive sample, there was some non-
response. Among the reasons for declining to take part
“feeling too unwell” or considering the study “too bur-
densome” were most frequently named, suggesting that
those who declined might have had more symptoms and
concerns and also might have had more difficulties
coping with the consequences of myeloma and its treat-
ment. However, this did not hinder us to recruit a sub-
stantial number of patients with relapsed or progressive
disease (32.7 %). The high number of patients during
treatment-free intervals and with stable disease points
towards the fact that the results from this study
under-represent the views of those that might have a
shorter and more acute disease trajectory and more
severe symptoms. Prevalence estimates for symptoms
might therefore be biased towards under-estimation.
The majority of patients were recruited from ter-
tiary cancer centres, although we tried to obtain a
mix of recruiting centres. More patients were sampled
from out-patient than from in-patient clinics. This led
to an under-representation of patients receiving stem
cell transplant at the time of the study (5 %) and
might have imbalanced the sample towards those with
higher functional performance status (only 9 % of pa-
tients had an ECOG performance status of 3 or 4). A
diverse patient group was included with diverse treat-
ment histories which makes it difficult to distinguish
between disease symptoms and treatment-related tox-
icities. A further limitation of our study is the lack of
collecting information on co-morbidities for patients.
This information was only available for a part of the
sample and could not be obtained validly from all
medical notes. We are aware that it is therefore not
possible to understand this potential confounding
factor.
This study uses a cross-sectional design. Therefore, in-
dependent variables in the regression analyses and any
correlation reported represent association but no predic-
tion. Moreover, this study did not follow patients as they
naturally progressed through different phases of disease.
Comparison between phases therefore relies on com-
parison between different patients. Physiological vari-
ables like haemoglobin, albumin or other variables that
indicate disease activity were not extracted from the
medical records and could not be considered in the
regression analysis.
Conclusions
This study showed the importance of regular assessment
of symptom burden and of quality of life in routine clin-
ical care. The current practice of one single holistic
needs assessment potentially misses periods of persist-
ently high problems, specifically pain, fatigue, breathless-
ness but also mental health problems that occur during
the advanced stages and even during treatment-free in-
tervals. The early integration of supportive and palliative
services for those experiencing high physical and emo-
tional symptoms could help improve symptom manage-
ment and therefore help maintain or optimise patient’s
quality of life. Focusing on traditional parameters to
monitor the disease progression might not help identify
those patients with myeloma that experience a low qual-
ity of life.
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tions of symptoms with EORTC QLQ –global quality of life scale, EQ5D
index and visual analogue (VAS) scale scores and the Myeloma Patient
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samples). Table S3. Bivariate associations of independent variables with the
the outcomes a) MyPOS total palliative care concerns, b) EQ5D Index, d)
Global health status (EORTC QLQ-C30), n = 557. (DOCX 42 kb)
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